Wellmarker Bio Stock

Wellmarker Bio Co., Ltd. is the first spin off company.

Sign up today and learn more about Wellmarker Bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Wellmarker Bio Stock

Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center. Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developing new drugs that overcome resistance of existing therapeutic approaches. Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer.

Funding History

October 2021$14.0B

Management

Founder and CEO

Dong-Hoon Jin

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo